Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Humira The drug that caused the most increased spending by far was Humira, a rheumatoid arthritis drug. (Photo: JB Reed/Bloomberg)

Drug price increases that were not supported by clinical improvements raised health care costs in the U.S. by about $1.67 billion in 2020, a new report said.

The report, released by The Institute for Clinical and Economic Review (ICER) said that among the top 10 drugs with price increases last year that had substantial effects on US spending, seven of 10 drugs did not have new evidence of a new clinical benefit. The group said these unsupported drug price increases cost the U.S. health system $1.67 billion, even after pharmaceutical rebates and other concessions.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?



Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO
Live Chat

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.